Nourish Medication Shows Strong Six-Month Persistence

New data reveals GLP-1 drug outperforms industry benchmarks for patient adherence.

Mar. 31, 2026 at 5:13pm

Got story updates? Submit your updates here. ›

A translucent X-ray photograph revealing the internal structures of the human digestive system, with a faint neon-like glow, conceptually representing the effectiveness of a new weight loss medication.Nourish's new GLP-1 medication shows promising long-term adherence rates, potentially improving weight loss outcomes for patients.NYC Today

A new report from Nourish, a pharmaceutical company, shows that its GLP-1 medication has achieved a 68% six-month persistence rate, outperforming typical industry benchmarks for this type of diabetes and weight loss drug. GLP-1 medications have shown promise for effective weight loss, but patient adherence has historically been a challenge.

Why it matters

Maintaining long-term adherence to GLP-1 medications is crucial for achieving the full weight loss and health benefits of these drugs. The high persistence rate demonstrated by Nourish's medication suggests it may be more effective at keeping patients on the treatment over an extended period compared to competitor products.

The details

The data from Nourish shows that 68% of patients remained on the company's GLP-1 medication for at least six months. This exceeds typical industry benchmarks for GLP-1 drug persistence, which often fall in the 40-50% range over a similar time period.

  • The data was reported on March 31, 2026.

The players

Nourish

A pharmaceutical company that develops diabetes and weight loss medications.

Got photos? Submit your photos here. ›

The takeaway

Nourish's strong six-month persistence data for its GLP-1 medication suggests the company may have developed a formulation or delivery method that helps patients better adhere to the treatment over the long term, which could lead to improved weight loss outcomes compared to other GLP-1 drugs on the market.